登录

Chemical.AI Extends Series A Financing by Additional $15 Million

作者: Mailman 2021-08-23 16:34
智化科技
https://www.chemical.ai/
企业数据由 动脉橙 提供支持
AI化学药物研发商 | B轮 | 运营中
中国-湖北
2022-10-18
融资金额:近亿人民币
长江创新
查看

(VCBeat) Aug. 08, 2021 -- Wuhan Zhihua Technology Co., Ltd. ("Chemical.AI") recently announced that it has completed an extended Series A round of nearly 15 million US dollars, led by Source Code Capital, with participation from Sequoia Capital China, FREES FUND and Huafang Capital. Proceeds from the transaction are mainly used for the construction and improvement of AI-based automated synthesis platform and marketing. Previously, the company received an angel round of investment from FREES FUND in 2019 and raised a Series A financing in 2021 led by Sequoia Capital China Seed Fund, with participation from Nest.Bio Ventures and FREES FUND.


Chemical.AI is a technology company driven by big data and AI, committed to using AI and big data in chemistry to solve the pre-clinical chemical synthesis problems of new drug R&D, in order to improve the efficiency of R&D for pharmaceutical companies. The founding team of Chemical.AI has been working in the field of chemical informatics for more than ten years and has rich experience in R&D. The company has accumulated a large number of professional data in chemical engineering. It is the pioneer in the field of chemical synthesis of new drugs based on AI in China.


Chemical.AI has explored in the field of chemical synthesis for many years and has made significant achievements in the phase of inverse synthesis. It promotes valuable data integration and reaction prediction with custom algorithms, and constantly improves the AI-based automated synthesis platform, thus assisting the work of R&D team. At present, Chemical.AI has established long-term cooperation with many large pharmaceutical companies and CRO giants around the world.


>>>>

About Source Code Capital


Since its inception in 2014, Source Code Capital has been committed to becoming the partner of choice for leading entrepreneurs in today's Information Revolution era with USD $ 1.5 billion and RMB 8.8 billion under management.


Source Code Capital invests across both early and growth stages. It is focused on the "Big 3" fundamental drivers, which are Internet+, AI+, and Global+ (China-angle companies in the international arena), and invest in sectors such as media and entertainment, consumer services, enterprise, finance, retail, transportation, housing, education, and healthcare.


>>>>

About Sequoia Capital China


Sequoia Capital China, as the "entrepreneur behind entrepreneur", focuses on investment in four directions including technology/media, healthcare, consumer goods/modern services and industrial technology. Over the past 15 years, Sequoia Capital China has invested in nearly 600 enterprises with distinctive technical characteristics, innovative business models, and high growth and development potential.

相关赛道 研发制造外包
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

【首发】新樾生物宣布完成数千万元Pre-A轮融资,加速推进DEL3.0技术平台建设及新药管线布局

【首发】哲源科技获近亿元A轮投资,用于“计算医学”平台升级和推进自研管线

【首发】AI制药明星企业英矽智能完成6000万美元D轮融资,将进一步推进其管线开发及自动化新药研发实验室的建设

【首发】晨兴数学奖获得者-哈佛刘军教授师生创建,角井生物完成数千万元融资

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

Jiabao Drug Bank Raises ¥100 Million in Pre-Series A Funding Round

2021-08-23
下一篇

Belle Healthcare Announces Close Of ¥100 Million Series B Financing Round

2021-08-23